Delcath Systems (NASDAQ:DCTH - Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Delcath Systems to post earnings of ($0.10) per share and revenue of $26.00 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.
Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.16. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. The firm had revenue of $29.13 million for the quarter, compared to analyst estimates of $26.25 million. On average, analysts expect Delcath Systems to post ($0.17) EPS for the current fiscal year and $0.12 EPS for the next fiscal year.
Delcath Systems Stock Performance
Shares of DCTH stock opened at $14.51 on Tuesday. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $17.42. The stock has a market cap of $503.50 million, a price-to-earnings ratio of 1,452.45 and a beta of 0.60. The firm has a fifty day moving average of $15.85 and a 200-day moving average of $12.25.
Analyst Ratings Changes
DCTH has been the topic of several recent research reports. Weiss Ratings upgraded shares of Delcath Systems from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, October 13th. Zacks Research lowered shares of Delcath Systems from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, October 6th. HC Wainwright restated a "buy" rating and set a $32.00 price target (up from $30.00) on shares of Delcath Systems in a research note on Friday, August 7th. Wall Street Zen raised Delcath Systems from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Finally, BTIG Research lifted their price objective on Delcath Systems from $17.00 to $21.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $24.50.
Read Our Latest Analysis on Delcath Systems
Delcath Systems Company Profile
(
Get Free Report)
Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.
Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company's proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.
Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Delcath Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.
While Delcath Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
